Immunovant (IMVT)
NASDAQ:IMVT
Want to see IMVT full AI Analyst Report?
IMVT Stock Chart & Stats
$29.30
-$0.80(-3.25%)
At close: 4:00 PM EST
$29.30
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$13.36 - $29.25
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.32M
Market Cap
$5.58B
Enterprise Value$4.97B
Total Cash (Recent Filing)$994.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Jun 03, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding203,532,180
10 Day Avg. Volume1,361,491
30 Day Avg. Volume1,322,041
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.20K
Enterprise Value/Ebitda-10.32
Forecast
1Y Price Target
$41.57Price Target Upside41.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.58
Revenue Forecast (FY)$6.64M
Bulls Say, Bears Say
Bulls Say
Dose-response BiologyEvidence that stronger initial dosing produced larger clinical effects than lower maintenance dosing suggests deeper IgG reduction could increase benefit and supports differentiation for next-generation FcRn assets.
Mechanism Of Action SupportTargeting thyroid-stimulating antibodies at the top of the disease cascade is expected to interrupt disease progression, reinforcing the scientific rationale for FcRn-targeting therapies in Graves' disease.
Next-generation Pipeline ExpansionDevelopment of IMVT-1402 across several autoimmune indications, including encouraging response observed in a cutaneous lupus case, expands potential commercial opportunities beyond the thyroid eye disease program.
Bears Say
Clinical Efficacy Setback In Thyroid Eye DiseasePhase 3 studies of batoclimab failed to meet the primary proptosis endpoint, raising uncertainty about the drug's ability to reverse established eye protrusion.
Financial And Market RiskHigh cash burn combined with meaningful short interest increases financial risk and could place additional downward pressure on the stock if clinical progress slows.
Reduced Addressable Patient PopulationExcluding patients with moderate-to-severe thyroid eye disease from the pivotal Graves' program limits the eligible patient pool and could constrain market opportunity for the therapy.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $13.36 and its highest was $29.25 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $5.58B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jun 03, 2026 which is in 46 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2026. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$0.713 by $0.103.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.6.
How many shares outstanding does Immunovant have?
Immunovant has 203,532,180 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.61 in its last earnings report, beating expectations of -$0.713. Following the earnings report the stock price went up 12.427%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.57 (41.88% Upside)
$41.57 (41.88% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 934.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $809.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.29%
12-Months-Change
Fundamentals
Return on Equity
-65.80%
Trailing 12-Months
Asset Growth
150.01%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum driven by exceptionally strong Phase II brepocitinib data in cutaneous sarcoidosis, multiple fully enrolled studies and a solid cash position to fund upcoming registrational activity. Key operational highlights include the brepo NDA in dermatomyositis, fully enrolled 1402 D2T RA and mosliciguat PH‑ILD studies, and constructive legal progress ahead of a March jury trial. Offsetting risks are the small size and baseline imbalances of the CS Phase II study (creating uncertainty aboutPhase III translation), ongoing litigation and evidentiary motions, continued high operating spend and typical regulatory/development timing uncertainties. Overall, the positives (clinical wins, pipeline momentum, enrollment success and cash runway) materially outweigh the programmatic and legal uncertainties identified on the call.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$41.57
▲(41.88% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---